Daclatasvir plus asunaprevir for HCV genotype 1b infection in patients with or without compensated cirrhosis: a pooled analysis-Reference-Cited by-同舟云学术

Daclatasvir plus asunaprevir for HCV genotype 1b infection in patients with or without compensated cirrhosis: a pooled analysis

Published:2016-01-24 Issue:7 Volume:36 Page:954-962
ISSN:1478-3223
Container-title:Liver International
language:en
Short-container-title:Liver Int

Author:

Kao Jia-Horng¹,Jensen Donald M.²,Manns Michael P.³⁴,Jacobson Ira⁵,Kumada Hiromitsu⁶,Toyota Joji⁷,Heo Jeong⁸,Yoffe Boris⁹,Sievert William¹⁰,Bessone Fernando¹¹,Peng Cheng-Yuan¹²,Roberts Stuart K.¹³,Lee Youn-Jae¹⁴,Bhore Rafia¹⁵,Mendez Patricia¹⁵,Hughes Eric¹⁵,Noviello Stephanie¹⁵

Affiliation:

1. Graduate Institute of Clinical Medicine; National Taiwan University College of Medicine and Hepatitis Research Center; National Taiwan University Hospital; Taipei Taiwan

2. Center for Liver Diseases; University of Chicago Medical Center; Chicago IL USA

3. Hannover Medical School; Hannover Germany

4. German Center for Infection Research; Hannover-Braunschweig Germany

5. Department of Medicine at Mount Sinai Beth Israel Medical Center; New York NY USA

6. Toranomon Hospital; Tokyo Japan

7. Sapporo-Kosei General Hospital; Sapporo Japan

8. College of Medicine; Pusan National University and Medical Research Institute; Pusan National University Hospital; Busan South Korea

9. Veterans Affairs Medical Center; Baylor College of Medicine; Houston TX USA

10. Monash Health and Monash University; Melbourne Victoria Australia

11. Hospital Provincial del Centenario; Servicio de Gastroenterología y Hepatología; Universidad Nacional de Rosario; Rosario Argentina

12. School of Medicine; China Medical University; Taichung Taiwan

13. Alfred Hospital and Monash University; Melbourne Victoria Australia

14. Inje University Busan Paik Hospital; Busan South Korea

15. Bristol-Myers Squibb Research and Development; Princeton NJ USA

Funder

Bristol-Myers Squibb

Publisher

Wiley

Subject

Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/liv.13049/fullpdf

Reference38 articles.

1. Global epidemiology and genotype distribution of the hepatitis C virus infection;Gower;J Hepatol,2014

2. World Health Organization Hepatitis C Key Facts. WHO factsheet No 164. July 2015 http://www.who.int/mediacentre/factsheets/fs164/en/

3. Hepatocellular carcinoma epidemiology;Bosetti;Best Pract Res Clin Gastroenterol,2014

4. European Association for the Study of the Liver EASL recommendations on treatment of hepatitis C 2015 http://www.easl.eu/medias/cpg/HEPC-2015/Full-report.pdf

5. American Association for the Study of Liver Diseases and the Infectious Diseases Society of America HCV guidance: recommendations for testing, managing, and treating hepatitis C http://www.hcvguidelines.org/full-report-view

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Animal Evidence for Synergistic Induction of Hepatic Injury by Dietary Fat and Alcohol Consumption and Its Potential Mechanisms;Journal of Personalized Medicine;2021-04-08

2. Consenso Mexicano para el Tratamiento de la Hepatitis C;Revista de Gastroenterología de México;2018-07

3. The Mexican consensus on the treatment of hepatitis C;Revista de Gastroenterología de México (English Edition);2018-07

4. Daclatasvir Plus Asunaprevir for the Treatment of Patients with Hepatitis C Virus Genotype 1b Infection: Real-World Efficacy, Changes in Liver Stiffness and Fibrosis Markers, and Safety;Gut and Liver;2018-05-15

5. Daclatasvir plus asunaprevir in treatment-naïve patients with hepatitis C virus genotype 1b infection;World Journal of Gastroenterology;2018-03-28